🏛️ Verified NIH Record • Updated 2026-07-16
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (NCT03706365)
🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).
Location: St. Joseph's Hospital and Medical Center — Phoenix, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior therapy with cytochrome P450 (CYP)17 inhibitors.
- Prior treatment with abemaciclib or any cyclin-dependent kinase (CDK) 4 \& 6 inhibitors.
- Prior cytotoxic chemotherapy for metastatic castration resistant prostate cancer (participants treated with docetaxel in the metastatic hormone-sensitive prostate cancer \[mHSPC\] are eligible). Prior radiopharmaceuticals for prostate cancer, or prior enzalutamide, apalutamide, darolutamide or sipuleucel-T. Participants who had prior radiation or surgery to all target lesions.
- Currently enrolled in a clinical study involving an investigational product.
- Gastrointestinal disorder affecting the absorption or ability to swallow large pills.
- Clinically significant heart disease, active or chronic liver disease, moderate/severe hepatic impairment (Child-Pugh Class B and C).
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (112 Sites)
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
- Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
- St. Bernards Medical Center — Jonesboro, Arkansas
- CBCC Global Research, Inc. — Bakersfield, California
- Providence St. Jude Medical Center — Fullerton, California
- Moores Cancer Center — La Jolla, California
- TRIO-US (Translational Research in Oncology-US) — Los Angeles, California
- UCLA Hematology/Oncology - Westwood (Building 100) — Los Angeles, California
- Pacific Cancer Care — Monterey, California
- Sansum Clinic_Kendle — Santa Barbara, California
- Rocky Mountain Cancer Center — Lone Tree, Colorado
- Millennium Oncology - Hollywood — Hollywood, Florida
- Northside Hospital — Atlanta, Georgia
- Fort Wayne Medical Oncology And Hematology at Parkview Comprehensive Cancer Center — Fort Wayne, Indiana
- Massachusetts General Hospital — Boston, Massachusetts
- M Health Fairview University of Minnesota Medical Center - East Bank — Minneapolis, Minnesota
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- New York Oncology Hematology (NYOH) - Clifton Park Cancer Center — Albany, New York
- Associated Medical Professionals - Urology — Syracuse, New York
- Research Medical Center — Nashville, Tennessee
- Baylor Scott & White Medical Center - Temple — Temple, Texas
- New York Oncology Hematology (NYOH) - Clifton Park Cancer Center — The Woodlands, Texas
- Northwest Cancer Specialists PC — The Woodlands, Texas
- Sansum Clinic_Kendle — The Woodlands, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.